AR079706A1 - Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso - Google Patents
Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y usoInfo
- Publication number
- AR079706A1 AR079706A1 ARP100104891A ARP100104891A AR079706A1 AR 079706 A1 AR079706 A1 AR 079706A1 AR P100104891 A ARP100104891 A AR P100104891A AR P100104891 A ARP100104891 A AR P100104891A AR 079706 A1 AR079706 A1 AR 079706A1
- Authority
- AR
- Argentina
- Prior art keywords
- angiogenesis
- treatment
- compositions
- methods
- diseases related
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000033115 angiogenesis Effects 0.000 title abstract 2
- 208000030533 eye disease Diseases 0.000 title abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- ZTYNVDHJNRIRLL-FWZKYCSMSA-N rhodostomin Chemical compound C([C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CSSC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(O)=O)[C@@H](C)O)=O)CSSC[C@H]2C(=O)N[C@H]3CSSC[C@@H](C(NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H]2NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)CN)CSSC2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N4)=O)CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC3=O)C(=O)N[C@@H](CCCCN)C(=O)N1)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=CC=C1 ZTYNVDHJNRIRLL-FWZKYCSMSA-N 0.000 abstract 1
- 108010049985 rhodostomin Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicacion 1: Una composicion para el tratamiento y/o la prevencion de una enfermedad ocular relacionada con la angiogénesis, la cual comprende una dosis baja de una variante de rodostomina que comprende una secuencia de aminoácidos seleccionada entre la SEC ID NO: 1 y la SEC ID NO: 16, o una sal farmacéuticamente aceptable de dicha variante de rodostamina. Reivindicacion 4: La composicion de acuerdo con la reivindicacion 1, en la cual dicha variante de rodostomina está conjugada con albumina o pegilada.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28962409P | 2009-12-23 | 2009-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079706A1 true AR079706A1 (es) | 2012-02-15 |
Family
ID=44151942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104891A AR079706A1 (es) | 2009-12-23 | 2010-12-22 | Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9044436B2 (es) |
| EP (1) | EP2515926A4 (es) |
| JP (1) | JP5739908B2 (es) |
| KR (1) | KR20120130752A (es) |
| CN (1) | CN102883738A (es) |
| AR (1) | AR079706A1 (es) |
| AU (1) | AU2010336475A1 (es) |
| BR (1) | BR112012015188A8 (es) |
| CA (1) | CA2782796A1 (es) |
| MX (1) | MX2012007416A (es) |
| NZ (1) | NZ600544A (es) |
| RU (1) | RU2012131251A (es) |
| TW (1) | TWI581801B (es) |
| WO (1) | WO2011079175A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3243835B1 (en) | 2009-02-11 | 2024-04-10 | Albumedix Ltd | Albumin variants and conjugates |
| AR077764A1 (es) * | 2009-07-20 | 2011-09-21 | Univ Nat Cheng Kung | Polipeptidos selectivos para integrina alfavbeta 3 conjugados a una variante de seroalbumina humana (hsa) y usos farmaceuticos de los mismos |
| ES2700230T3 (es) | 2009-10-30 | 2019-02-14 | Albumedix Ltd | Variantes de albúmina |
| CN106977608A (zh) | 2010-04-09 | 2017-07-25 | 阿尔布麦狄克斯公司 | 白蛋白衍生物和变体 |
| WO2013075066A2 (en) | 2011-11-18 | 2013-05-23 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| MX2014010278A (es) | 2012-03-16 | 2015-03-05 | Novozymes Biopharma Dk As | Variantes de albumina. |
| EP2917233A1 (en) | 2012-11-08 | 2015-09-16 | Novozymes Biopharma DK A/S | Albumin variants |
| WO2015147616A1 (ko) * | 2014-03-28 | 2015-10-01 | 연세대학교 산학협력단 | Rgd 모티프를 포함하는 펩타이드 또는 단백질을 포함하는 신경염증 예방, 억제 또는 치료용 조성물 |
| US10508137B2 (en) * | 2014-08-22 | 2019-12-17 | National Cheng Kung Univeristy | Disintegrin variants and pharmaceutical uses thereof |
| US10463720B2 (en) | 2014-12-31 | 2019-11-05 | Huons Co., Ltd. | Composition, containing RGD motif-containing peptide or fragment thereof, for treating burns and glaucoma, alleviating skin wrinkles, and promoting hair growth |
| ES2797901T3 (es) * | 2015-06-28 | 2020-12-04 | Allgenesis Biotherapeutics Inc | Proteínas de fusión para la inhibición de angiogénesis |
| WO2017029407A1 (en) | 2015-08-20 | 2017-02-23 | Albumedix A/S | Albumin variants and conjugates |
| US12304037B2 (en) | 2021-11-03 | 2025-05-20 | Aob Products Company | Torque driver |
| US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
| KR20250021281A (ko) | 2023-08-04 | 2025-02-12 | 주식회사 넥스세라 | 콜라겐 타입 i 및 색소 상피성 인자 펩타이드를 유효성분으로 포함하는 안구 혈관신생 질환의 예방 또는 치료용 점안제 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US6710030B1 (en) * | 1993-10-22 | 2004-03-23 | University Of Southern California | Contortrostain (CN) and methods for its use in preventing metastasis and other conditions |
| US5659018A (en) * | 1995-08-01 | 1997-08-19 | Genetics Institute, Inc. | Mocarhagin, a cobra venom protease, and therapeutic uses thereof |
| WO2003042354A2 (en) * | 2001-09-04 | 2003-05-22 | Aventis Pharmaceuticals Inc. | Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis |
| EP1534718A4 (en) | 2002-06-07 | 2006-06-07 | Wisconsin Alumni Res Found | CHEMICAL SYNTHESIS OF REAGENTS FOR PEPTIDE COUPLING |
| JP2008540342A (ja) * | 2005-04-29 | 2008-11-20 | リサーチ ディベロップメント ファウンデーション | 眼の新生血管形成の血管標的化 |
| US7943728B2 (en) * | 2006-12-26 | 2011-05-17 | National Cheng Kung University | Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases |
| AR077764A1 (es) * | 2009-07-20 | 2011-09-21 | Univ Nat Cheng Kung | Polipeptidos selectivos para integrina alfavbeta 3 conjugados a una variante de seroalbumina humana (hsa) y usos farmaceuticos de los mismos |
-
2010
- 2010-12-22 WO PCT/US2010/061738 patent/WO2011079175A1/en not_active Ceased
- 2010-12-22 CN CN2010800594090A patent/CN102883738A/zh active Pending
- 2010-12-22 BR BR112012015188A patent/BR112012015188A8/pt not_active IP Right Cessation
- 2010-12-22 JP JP2012546185A patent/JP5739908B2/ja not_active Expired - Fee Related
- 2010-12-22 EP EP20100840104 patent/EP2515926A4/en not_active Withdrawn
- 2010-12-22 NZ NZ600544A patent/NZ600544A/en not_active IP Right Cessation
- 2010-12-22 CA CA2782796A patent/CA2782796A1/en not_active Abandoned
- 2010-12-22 KR KR1020127019529A patent/KR20120130752A/ko not_active Withdrawn
- 2010-12-22 AR ARP100104891A patent/AR079706A1/es unknown
- 2010-12-22 MX MX2012007416A patent/MX2012007416A/es not_active Application Discontinuation
- 2010-12-22 AU AU2010336475A patent/AU2010336475A1/en not_active Abandoned
- 2010-12-22 RU RU2012131251/15A patent/RU2012131251A/ru not_active Application Discontinuation
- 2010-12-22 US US12/975,630 patent/US9044436B2/en not_active Expired - Fee Related
- 2010-12-23 TW TW099145616A patent/TWI581801B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012015188A8 (pt) | 2016-08-09 |
| US20110152192A1 (en) | 2011-06-23 |
| WO2011079175A1 (en) | 2011-06-30 |
| TWI581801B (zh) | 2017-05-11 |
| AU2010336475A1 (en) | 2012-06-14 |
| KR20120130752A (ko) | 2012-12-03 |
| TW201138801A (en) | 2011-11-16 |
| NZ600544A (en) | 2014-06-27 |
| MX2012007416A (es) | 2012-07-23 |
| EP2515926A4 (en) | 2013-10-09 |
| EP2515926A1 (en) | 2012-10-31 |
| US9044436B2 (en) | 2015-06-02 |
| CN102883738A (zh) | 2013-01-16 |
| JP2013515739A (ja) | 2013-05-09 |
| BR112012015188A2 (pt) | 2016-04-05 |
| RU2012131251A (ru) | 2014-01-27 |
| JP5739908B2 (ja) | 2015-06-24 |
| CA2782796A1 (en) | 2011-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079706A1 (es) | Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso | |
| PE20241305A1 (es) | Analogos de amilina | |
| UA113165C2 (xx) | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| AR083679A1 (es) | Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos | |
| AR059575A1 (es) | Metodo para el tratamiento de enfermedades inflamatorias | |
| BRPI0509863A (pt) | liberação de fármaco para fundo de olho | |
| JP2013520405A5 (es) | ||
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| CR9721A (es) | Compuestos de carbamato para utilizar en el tratamiento de desordenes neurodegenerativos | |
| BR112014003225A2 (pt) | profármacos de treprostinil ligados a veículo | |
| MX362382B (es) | Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas. | |
| AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
| UY32691A (es) | Compuestos de 1h-imidazo-[4,5-c]-quinolinona | |
| AR039164A1 (es) | Sales de venlafaxina de baja solubilidad en agua | |
| DOP2007000053A (es) | Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo | |
| HRP20160392T1 (hr) | Cjepivo pcsk9 | |
| PE20171622A1 (es) | Formulacion de relacion fija de insulina glargina/lixisenatida | |
| WO2015183995A3 (en) | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | |
| BR112012016783A2 (pt) | "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia" | |
| AR068438A1 (es) | Derivado de 6-pirimidinil-pirimid-2-ona | |
| CL2021003312A1 (es) | Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| CO6280474A2 (es) | Composicion farmaceutica para el tratamiento de la eyaculacion precoz | |
| AR068439A1 (es) | Derivado de 6-pirimidinil-pirimid-2-ona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |